MiMedx Group proposes merging Sanara MedTech into a wholly owned subsidiary, giving each eligible Sanara share $33.00 in cash and 0.4735 MiMedx shares. The structure matters because Sanara shareholders must approve it, and the stock portion’s Market Value will fluctuate with MiMedx shares before closing.
Key Highlights
- MiMedx and Sanara entered a Merger agreement on July 29, 2026.
- Each eligible Sanara share would receive $33.00 in cash and 0.4735 MiMedx shares.
- Sanara shareholders will vote on the merger at a virtual special meeting on September 30, 2026.
MiMedx Group, Inc. (NASDAQ: MDXG) entered an agreement to merge with Sanara MedTech, under which each eligible Sanara share would receive $33.00 in cash and 0.4735 MiMedx shares.
September 30 Vote Will Decide Proposed Merger
The merger agreement was signed on July 29, 2026, among MiMedx, Mustang Merger Sub and Sanara. Sanara would survive the transaction as a wholly owned MiMedx subsidiary. Sanara’s special meeting will be held virtually on September 30, 2026, with shareholders voting on the merger, an advisory compensation proposal and a possible adjournment. MiMedx and Sanara cannot complete the transaction without approval of the merger proposal. Sanara’s board unanimously approved the agreement and recommended that shareholders adopt it.
Implied Consideration Reaches $35.14
MiMedx common stock closed at $4.36 and Sanara common stock at $26.64 on July 28, 2026, producing implied merger consideration of $35.06 per Sanara share. On September 1, MiMedx closed at $4.52 and Sanara at $34.79, while the implied consideration was $35.14. The stock component’s market value will fluctuate with MiMedx’s share price.
FAQs
Q: What are Sanara shareholders receiving in the MiMedx merger?
A: Each eligible Sanara share would be converted into $33.00 in cash and 0.4735 MiMedx shares, subject to adjustment and applicable withholding taxes.
Q: What must happen before the MiMedx Sanara merger can close?
A: Sanara shareholders must approve the merger proposal at the September 30, 2026, virtual special meeting before MiMedx and Sanara can complete the transaction.
Q: What does the filing say about the stock component’s market value?
A: The stock component’s market value will fluctuate with MiMedx’s share price. The implied merger consideration was $35.06 on July 28 and $35.14 on September 1.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.